ClinicalTrials.gg
Active, not recruitingNCT04033679Updated Aug 25, 2026

The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia

An interventional study of Active TDCS and Sham TDCS in Schizophrenia;Schizoaffective, sponsored by Centre for Addiction and Mental Health. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Psychotic Disorders by Centre for Addiction and Mental Health — 4 open to participants now, 8 under way, none of them phase 3. Psychotic Disorders · Centre for Addiction and Mental Health.

Planned enrollment
6th of 35
106 · median 50
Started
2019
the only one that year
No phase
31 of 37
3 open now
Registered
27th of 37
by date

Among the 37 studies in Psychotic Disorders by Centre for Addiction and Mental Health, this one is the 6th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2019, is one of 31 with no phase, and was the 27th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 37 studies in Psychotic Disorders by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Psychotic Disorders by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (SCZ). The investigators hypothesize that 20 sessions of tDCS will improve medication nonadherence in patients with SCZ.

Read the detailed description

The proposed study will investigate the effects of adjunctive tDCS on antipsychotic medication adherence by targeting brain regions implicated in impaired insight, a primary contributor to medication nonadherence in patients with SCZ. Participants will be randomized to receive either active or sham tDCS. tDCS will be administered twice-daily for 10 days (20 sessions) excluding weekends. Brain scans will be performed before and after 10 days of tDCS. Antipsychotic drug adherence will be assessed based primarily on pill-count, and secondarily, plasma level concentrations and clinician-judgement.

03

Conditions studied

  • Schizophrenia;Schizoaffective

Keywords

  • Magnetic resonance imaging
  • Brain stimulation
  • Medication adherence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients ≥18 years of age
  3. diagnosis of SCZ or schizoaffective disorder
  4. Capable of consenting to participate in the research study
  5. On a stable dose of antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence
  2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures
  3. Acute suicidal or homicidal ideation
  4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item
  5. substance dependence (except caffeine and nicotine) within 1 month of entering the study*
  6. Positive urine drug screen except for cannabis/marijuana at the screening visit
  7. Metal implants or pacemaker precluding an MRI scan or other to MRI (eg., claustrophobia)
  8. Pregnancy
  9. Score \< 32 on the Wide Range Achievement Test-III

    • Substance misuse: In addition to impaired insight, substance misuse is one of the principle contributors to medication nonadherence. To minimize the possibility of its influence, participants with a DSM-V diagnosis of substance dependence within 1 month of entering the study or a positive urine drug test (except for cannabis/marijuana) at the screening visit will be excluded. Substance use and urine drug screens will be assessed at subsequent study visits.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Active TDCS

    In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.

    Other: Active TDCS

  • Sham comparator
    Sham TDCS

    In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.

    Other: Sham TDCS

Interventions

  • OtherActive TDCS

    Participants will receive active TDCS stimulation.

  • OtherSham TDCS

    Participants will receive sham TDCS stimulation.

06

What researchers measure

Primary outcomes

  1. Medication adherence - Pill Count

    Pill count or percentage of weekly antipsychotic medication adherence will be assessed during the 3-month follow up phase after TDCS is completed.

    Time frame: During 3-month follow up phase

  2. Medication adherence - Plasma Monitoring

    Blood concentrations of antipsychotic medication will be measured at different points in the study to assess medication adherence.

    Time frame: Blood concentration of antipsychotic medication will be measured on day of the first TDCS session before TDCS starts, after 1 week of TDCS is completed, after 2 weeks of TDCS are completed, and during the 3-month follow up phase.

  3. Medication adherence - Clinician Rating

    The Clinician Adherence Rating Scale is a 7-point clinician rated measure which takes into account patients' self-report, medication adherence, and changes in plasma concentrations to provide a comprehensive assessment of antipsychotic medication adherence. A higher score represents greater adherence.

    Time frame: During 3-month follow up phase

Secondary outcomes

  1. Insight into Psychosis

    Level of illness awareness will be assessed by the VAGUS Insight into Psychosis scale. The VAGUS assesses the core domains of insight into psychosis. VAGUS has both self-report and clinician-rated versions with good inter-scale reliability and test-retest reliability. Higher scores indicate better insight into illness.

    Time frame: Illness awareness will be assessed before the TDCS phase begins, after 2 weeks of TDCS are completed, and during the 3-month follow up period

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Mar 2027, 91 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 91 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2019
First posted
Jul 26, 2019
StartActual
Aug 15, 2019
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04033679
Responsible party
Philip Gerretsen (Clinicial Scientist, Centre for Addiction and Mental Health) — Principal investigator
First posted
Jul 26, 2019
Start date
Aug 15, 2019
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Philip Gerretsen, MD, PhD
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion